flumazenil has been researched along with Alcohol Abuse in 23 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benzodiazepine receptor antagonist flumazenil reduces anxiety-like behavior and sensitization of anxiety-like behavior in various models of ethanol withdrawal in rodents." | 7.74 | The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress. ( Angel, RA; Breese, GR; Knapp, DJ; Navarro, M; Overstreet, DH, 2007) |
| "Disulfiram is an aldehyde dehydrogenase inhibitor that is widely used as an adjunctive agent in the treatment of patients with severe chronic alcoholism." | 7.69 | Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. ( Adams, KM; Gilman, S; Heumann, M; Hill, E; Johnson-Greene, D; Junck, L; Kluin, KJ; Koeppe, RA; Martorello, S, 1996) |
| "The benzodiazepine receptor antagonist flumazenil reduces anxiety-like behavior and sensitization of anxiety-like behavior in various models of ethanol withdrawal in rodents." | 3.74 | The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress. ( Angel, RA; Breese, GR; Knapp, DJ; Navarro, M; Overstreet, DH, 2007) |
| "Disulfiram is an aldehyde dehydrogenase inhibitor that is widely used as an adjunctive agent in the treatment of patients with severe chronic alcoholism." | 3.69 | Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. ( Adams, KM; Gilman, S; Heumann, M; Hill, E; Johnson-Greene, D; Junck, L; Kluin, KJ; Koeppe, RA; Martorello, S, 1996) |
| " Flumazenil was efficient for leading out from coma in 86% of cases with poisoning only by benzodiazepines and 13% of cases with mixed intoxications mainly containing benzodiazepines and alcohol or carbamazepine." | 3.69 | [Suicidal poisoning with benzodiazepines]. ( Chodorowski, Z; Sein Anand, J, 1997) |
| "Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently." | 2.74 | Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. ( Anton, RF; Baros, AM; Latham, PK; Malcolm, R; Myrick, H; Randall, PK; Stewart, SH; Waid, R; Wright, TM, 2009) |
| "Abstinent male alcohol dependent subjects underwent [11C]flumazenil PET to measure occupancy of BDZ receptors by midazolam whilst recording its pharmacodynamic effects on behavioural and physiological measures." | 2.71 | GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. ( Brooks, DJ; Cunningham, VJ; Feeney, A; Lingford-Hughes, AR; Nutt, DJ; Stevenson, B; Wilson, SJ, 2005) |
| "He was treated for hepatic encephalopathy with complete recovery and resolution of the neurologic findings." | 2.46 | Reversible hepatic decerebration: a case report and review of the literature. ( Antoun, SA; Delgado, F; Saad, D; Ta, H; Wehbe, E, 2010) |
| "Men with alcohol dependence (n = 27) and a matched healthy comparison group (n = 15)." | 1.33 | Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. ( Baldwin, R; Frohlich, E; Gottschalk, C; Gueorguieva, R; Innis, RB; Jatlow, P; Krystal, JH; O'Malley, S; Perry, E; Petrakis, IL; Ruff, E; Seibyl, JP; Staley, JK; van Dyck, CH; Verhoeff, NP; Weinzimmer, D, 2005) |
| "Although alcohol dependence in women is an increasing problem, little is known about the effects of alcohol on the female brain." | 1.31 | Levels of gamma-aminobutyric acid-benzodiazepine receptors in abstinent, alcohol-dependent women: preliminary findings from an 123I-iomazenil single photon emission tomography study. ( Acton, PD; Boddington, SJ; Costa, DC; Ell, PJ; Gacinovic, S; Kerwin, RW; Lingford-Hughes, AR; Marshall, EJ; Pilowsky, LS, 2000) |
| "[11C]Flumazenil binding was quantified by applying a saturation procedure with two PET experiments, the first with high (400-3400 Ci/mmol) and the second with low (approximately 1 Ci/mmol) specific radioactivity." | 1.29 | PET analysis of [11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls. ( Farde, L; Halldin, C; Hindmarsh, T; Litton, JE; Neiman, J; Pauli, S; Sedvall, G, 1993) |
| "Flumazenil treatment of ethanol-dependent mice 14 hr before isolation of brain membrane vesicles partially reversed the augmentation of Ro15-4513 inhibition of muscimol-stimulated 36Cl- uptake in vitro." | 1.28 | Reversal of alcohol dependence and tolerance by a single administration of flumazenil. ( Buck, KJ; Harris, RA; Heim, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, W | 1 |
| Majumder, S | 1 |
| Clayton, T | 1 |
| Petrou, S | 1 |
| VanLinn, ML | 1 |
| Namjoshi, OA | 1 |
| Ma, C | 1 |
| Cromer, BA | 1 |
| Roth, BL | 1 |
| Platt, DM | 1 |
| Cook, JM | 1 |
| Lucyk, S | 1 |
| von Schweinitz, BA | 1 |
| Hoffman, RS | 1 |
| Moore, PW | 1 |
| Hieger, MA | 1 |
| Donovan, JW | 1 |
| Wehbe, E | 1 |
| Saad, D | 1 |
| Delgado, F | 1 |
| Ta, H | 1 |
| Antoun, SA | 1 |
| Anton, RF | 3 |
| Myrick, H | 3 |
| Baros, AM | 2 |
| Latham, PK | 2 |
| Randall, PK | 3 |
| Wright, TM | 2 |
| Stewart, SH | 1 |
| Waid, R | 1 |
| Malcolm, R | 1 |
| Schacht, JP | 2 |
| Waid, LR | 1 |
| Li, X | 1 |
| Henderson, S | 1 |
| Lingford-Hughes, AR | 2 |
| Wilson, SJ | 1 |
| Cunningham, VJ | 1 |
| Feeney, A | 1 |
| Stevenson, B | 1 |
| Brooks, DJ | 1 |
| Nutt, DJ | 1 |
| Staley, JK | 1 |
| Gottschalk, C | 1 |
| Petrakis, IL | 2 |
| Gueorguieva, R | 1 |
| O'Malley, S | 1 |
| Baldwin, R | 1 |
| Jatlow, P | 1 |
| Verhoeff, NP | 1 |
| Perry, E | 1 |
| Weinzimmer, D | 1 |
| Frohlich, E | 1 |
| Ruff, E | 1 |
| van Dyck, CH | 1 |
| Seibyl, JP | 2 |
| Innis, RB | 2 |
| Krystal, JH | 2 |
| Knapp, DJ | 1 |
| Overstreet, DH | 1 |
| Angel, RA | 1 |
| Navarro, M | 1 |
| Breese, GR | 1 |
| Farde, L | 2 |
| Pauli, S | 2 |
| Litton, JE | 2 |
| Halldin, C | 2 |
| Neiman, J | 2 |
| Sedvall, G | 2 |
| Hindmarsh, T | 1 |
| Gilman, S | 1 |
| Adams, KM | 1 |
| Johnson-Greene, D | 1 |
| Koeppe, RA | 1 |
| Junck, L | 1 |
| Kluin, KJ | 1 |
| Martorello, S | 1 |
| Heumann, M | 1 |
| Hill, E | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Abi-Dargham, A | 1 |
| Anjilvel, S | 1 |
| Scanley, BE | 1 |
| Zoghbi, S | 1 |
| Baldwin, RM | 1 |
| Rajeevan, N | 1 |
| Ellis, S | 1 |
| Charney, DS | 1 |
| Laruelle, M | 1 |
| Acton, PD | 1 |
| Gacinovic, S | 1 |
| Boddington, SJ | 1 |
| Costa, DC | 1 |
| Pilowsky, LS | 1 |
| Ell, PJ | 1 |
| Marshall, EJ | 1 |
| Kerwin, RW | 1 |
| Buck, KJ | 1 |
| Heim, H | 1 |
| Harris, RA | 1 |
| López Soriano, F | 1 |
| García Basterrechea, JM | 1 |
| Hallal Hachem, H | 1 |
| Alguacil García, GF | 1 |
| Mhatre, M | 1 |
| Ticku, MK | 1 |
| Chan, AW | 1 |
| Kurshed, AAM | 1 |
| Vincze, F | 2 |
| Pikó, P | 1 |
| Kósa, Z | 1 |
| Sándor, J | 2 |
| Ádány, R | 2 |
| Diószegi, J | 1 |
| Nagy, A | 1 |
| Földvári, A | 1 |
| Szabó, E | 1 |
| Csenteri, O | 1 |
| Sipos, V | 1 |
| Kovács, N | 1 |
| Pálinkás, A | 1 |
| Papp, M | 1 |
| Fürjes, G | 1 |
| Ekuklu, G | 1 |
| Deveci, S | 1 |
| Eskiocak, M | 1 |
| Berberoglu, U | 1 |
| Saltik, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention[NCT00262639] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670] | 140 participants (Anticipated) | Interventional | 2018-11-14 | Active, not recruiting | |||
| Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence[NCT01904487] | Phase 1 | 11 participants (Actual) | Interventional | 2011-04-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6
| Intervention | percent days (Mean) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 70.8 |
| Low CIWAar Placebo | 86.1 |
| High CIWAar Placebo | 75.9 |
| High CIWAar Flumazenil/Gabapentin | 95.9 |
percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial
| Intervention | percent of participants (Number) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 44 |
| Low CIWAar Placebo | 19 |
| High CIWAar Placebo | 33 |
| High CIWAar Flumazenil/Gabapentin | 71 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
1 review available for flumazenil and Alcohol Abuse
| Article | Year |
|---|---|
Reversible hepatic decerebration: a case report and review of the literature.
Topics: Alcoholism; Decerebrate State; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Alcoholi | 2010 |
4 trials available for flumazenil and Alcohol Abuse
| Article | Year |
|---|---|
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Brain; Cues; Cyclohexanecarboxylic Acids; Drug Therapy, | 2013 |
GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study.
Topics: Adult; Alcoholism; Analysis of Variance; Blood Pressure; Brain; Case-Control Studies; Competitive Bi | 2005 |
18 other studies available for flumazenil and Alcohol Abuse
| Article | Year |
|---|---|
Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.
Topics: Alcoholism; Animals; Benzodiazepines; Binding Sites; Carbolines; Cell Line; Computer Simulation; GAB | 2010 |
In response to: safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.
Topics: Alcoholism; Antidotes; Benzodiazepines; Delirium; Flumazenil; Humans; Retrospective Studies; Substan | 2014 |
The toxicologist and delirium: flumazenil as a diagnostic and therapeutic tool for delirium during the course of alcohol withdrawal.
Topics: Alcoholism; Benzodiazepines; Delirium; Flumazenil; Humans; Substance Withdrawal Syndrome | 2014 |
Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking.
Topics: Adult; Alcoholism; Cerebral Cortex; Comorbidity; Ethanol; Flumazenil; Humans; Iodine Radioisotopes; | 2005 |
The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress.
Topics: Alcohol Drinking; Alcoholism; Amygdala; Animals; Anxiety; Behavior, Animal; Body Weight; Disease Mod | 2007 |
PET-determination of benzodiazepine receptor binding in studies on alcoholism.
Topics: Adult; Alcoholism; Brain; Carbon Radioisotopes; Cerebellum; Cerebral Cortex; Flumazenil; Humans; Mal | 1994 |
PET analysis of [11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls.
Topics: Adult; Alcoholism; Brain; Carbon Radioisotopes; Flumazenil; Humans; Kinetics; Magnetic Resonance Ima | 1993 |
Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Blood Glucose; Brain; Deoxyglucose; Disulfiram; Energy | 1996 |
[Suicidal poisoning with benzodiazepines].
Topics: Adolescent; Adult; Aged; Alcoholism; Benzodiazepines; Carbamazepine; Coma; Ethanol; Female; Flumazen | 1997 |
Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil.
Topics: Adult; Alcoholism; Brain; Cerebellum; Cerebral Cortex; Flumazenil; Frontal Lobe; Gyrus Cinguli; Huma | 1998 |
Levels of gamma-aminobutyric acid-benzodiazepine receptors in abstinent, alcohol-dependent women: preliminary findings from an 123I-iomazenil single photon emission tomography study.
Topics: Adult; Alcoholism; Brain; Brain Chemistry; Cerebellum; Female; Flumazenil; Humans; Male; Middle Aged | 2000 |
Reversal of alcohol dependence and tolerance by a single administration of flumazenil.
Topics: Alcoholism; Animals; Ataxia; Behavior, Animal; Brain; Carbolines; Chlorides; Drug Administration Sch | 1991 |
[Can flumazenil counteract the central effects of alcohol?].
Topics: Adult; Alcoholism; Ethanol; Female; Flumazenil; Humans; Male | 1990 |
Chronic ethanol treatment selectively increases the binding of inverse agonists for benzodiazepine binding sites in cultured spinal cord neurons.
Topics: Alcoholism; Animals; Azides; Benzodiazepines; Cells, Cultured; Female; Flumazenil; Flunitrazepam; Ma | 1989 |
Ethanol and chlordiazepoxide cross-dependence.
Topics: Alcoholism; Animals; Chlordiazepoxide; Flumazenil; Male; Mice; Mice, Inbred C57BL; Substance Withdra | 1987 |
Taste Preference-Related Genetic Polymorphisms Modify Alcohol Consumption Behavior of the Hungarian General and Roma Populations.
Topics: Alcohol Drinking; Alcoholism; Humans; Hungary; Polymorphism, Genetic; Roma; Taste | 2023 |
Delivery of cardio-metabolic preventive services to Hungarian Roma of different socio-economic strata.
Topics: Adult; Alcoholism; Blood Glucose; Cholesterol; Cross-Sectional Studies; Delivery of Health Care; Edu | 2017 |
Alcoholism prevalence and some related factors in Edirne, Turkey.
Topics: Adolescent; Adult; Alcoholism; Female; Humans; Male; Middle Aged; Prevalence; Risk Factors; Roma; Tu | 2004 |